Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Colon Cancer treatment details. Biologic therapy. The Queen Elizabeth Hospital and University of Adelaide, Woodville, SA, Australia

Survival: 10.0 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: Australia
City/State/Province: Woodville, SA
Hospital: The Queen Elizabeth Hospital and University of Adelaide
Journal: Link
Date: 4/2014

This phase 3 study involved previously treated metastatic colorectal cancer patients with wild-type KRAS exon 2 cancer who were divided into two separate treatment groups. Group A consisted of 499 patients with a median age of 61 years; 63% were male. Group B had 500 patients with a median age of 60.5 years; 64% were male.

Patients in group A were treated with the biologic therapy agent panitumumab, which is an anti-EGFR monoclonal antibody that interferes with cancer cell growth.

Patients in group B were treated with a similar biologic therapy agent called cetuximab.

Adverse event-related deaths due to kidney failure and sepsis were reported in group A. Grade 4 low magnesium, diarrhea and fatigue were also reported.

Adverse event-related deaths due to lung infection were reported in group B. Grade 4 anemia and infusion reactions were also reported.

The median overall survival rates for groups A and B were 10.4 and 10.0 months, respectively.

This study was supported by Amgen, Inc.

Correspondence: Dr. Timothy J Price; email:

E-mail to a Friend Email Physician More Information